CD24 Protein-VLP (AA 26-57)

N° du produit ABIN7448155

Protéine VLP CD24 exprimée dans HEK-293 Cells.

Aperçu rapide pour CD24 Protein-VLP (AA 26-57) (ABIN7448155)

Antigène: CD24 (CD24 Molecule (CD24))

Type de proteíne: VLP

Activité biologique: Active

Origine: Cynomolgus

Source: HEK-293 Cells

Application: ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Pureté: > 90 % as determined by HPLC

Détail du produit

Attributs du protein: AA 26-57

Fonction: Cynomolgus CD24 VLP

Séquence: Ser26-Gly57

Attributs du produit: Recombinant Cynomolgus CD24 VLP is expressed from HEK293.It contains Ser26-Gly57 (It may have cross reaction with anti-His antibody).

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1 EU per μg by the LAL method.

Biological Activity Comment: The purity of Cynomolgus CD24 VLP is greater than 90% as determined by SEC-HPLC.

Information d'application

Indications d'application:

• Antibody Discovery: Immunization, Screening, Functional Characterization
• Affinity determination: ELISA, SPR
• In vivo pharmacokinetic analysis
• CMC method development
• CAR-T Positive Rate Detection
• Blood sample determination: ELISA

Commentaires:

Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1 mg/mL for 500 μg or 1 mg lyophilized powder. Do not mix by vortex or vigorous shaking.

Buffer: Lyophilized from 0.22 μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C

Stockage commentaire: -20°C or lower for 12 months as supplied from date of receipt.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: CD24 (CD24 Molecule (CD24))

Autre désignation: CD24

Sujet: CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

Poids moléculaire: 3.8 kDa.

NCBI Accession: XP_015304503

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation